Article
What can NPs, PAs, and physicians say publicly about peptides, hormones, and longevity therapies without compliance risk?
NPs, PAs, and physicians can publicly explain what a peptide, hormone, or longevity therapy is, what the evidence shows, its regulatory status, and its risks. Medical advertising compliance risk starts when content helps someone get, dose, prepare, or inject a drug, or implies it is FDA approved, equal to an approved drug, safe, or effective without evidence.
FDA warned 30 telehealth companies in March 2026 over compounded GLP-1 claims, and the FTC says a disclaimer "can't directly contradict a claim." The same rules apply whether you are an NP, a PA, or a physician.
On October 29, 2026, Meta's Oversight Board overturned the removal of an Instagram video about prescription drugs used in pregnancy and childbirth. Meta removed the post under its Restricted Goods and Services policy. The Board found it fell within the exception for prescription drugs in a medical context.
That case shows two things clinicians need to know. Legitimate medical discussion is allowed, and it can still be removed by mistake. Neither fact makes drug promotion safe.
This page sets out where federal regulators draw the line between education and promotion, what each major platform allows, how to write a case study, and a checklist to run before you post. Regulatory statements are dated as of November 2, 2026.
Where does education end and promotion begin?
The line is the purpose and practical effect of the content, not its label. Scriptura's working test:
- Educational content explains what a compound is, what the literature reports, what remains unknown, what risks clinicians evaluate, what regulators have said, and how a licensed clinician reasons.
- Promotional or facilitating content helps the reader obtain, select, calculate, prepare, dose, inject, or self-administer the drug, or implies it is approved, equivalent, safe, or right for the reader.
The test applies equally to NPs, PAs, and physicians. The FTC's Health Products Compliance Guidance applies to whoever makes the claim, and state boards hold their own licensees accountable. The Federation of State Medical Boards' model social media guidelines, reproduced by the Maine Board of Licensure in Medicine, say boards "have the authority to discipline physicians for unprofessional behavior" online. NP and PA conduct falls under the board that licenses them in each state.
So can NPs and PAs advertise peptide therapy? They can advertise their services where state law allows. The claims in that advertising face the same FDA, FTC, and platform rules as a physician's.
Can clinicians post dosing or reconstitution content if it is labelled educational?
Scriptura's view is no. A label doesn't change what the content does. FDA's August 2026 warning letters, covered below, treated peptide calculators and bacteriostatic water as evidence that products were meant for human injection, despite "research use only" labels. Step-by-step dosing, reconstitution, or injection content for a peptide works the same way, whatever the caption says.
What does FDA say about marketing compounded and investigational drugs?
FDA's March 2026 letters to 30 telehealth companies objected to claims implying compounded GLP-1s were identical to FDA-approved drugs, obscuring the source of the medication, and implying the products were generics, Drug Topics reported. About 25 more letters followed in mid-June, according to Arent Fox Schiff.
Those letters went to telehealth companies, not individual clinicians. But a clinic that markets a compounded drug online uses the same kinds of claims, so Scriptura treats FDA's list as the standard for clinic content too.
What can clinics say about compounded drugs online?
You can say what the drug is, that it is compounded, and that it is not FDA-approved. FDA's guidance for telehealth companies, current as of June 15, 2026, lists claims to avoid. Don't describe a compounded drug as:
- "a generic version of an FDA-approved drug."
- "the same as a drug approved by FDA."
- "clinically proven to produce the same result as the FDA-approved drug."
- FDA-approved or evaluated for safety and effectiveness.
- Coming from an "FDA-approved or FDA-licensed pharmacy." FDA doesn't approve or license any facility.
The same applies to the six peptides under HHS's October 2026 enforcement discretion policy. Its Federal Register notice states that "compounded drugs are not FDA-approved." Under 21 CFR 216.23, calling a compounded drug made from a listed bulk substance FDA approved "will cause the drug to be misbranded."
So can a clinic advertise compounded semaglutide on Facebook or Instagram? Only within the FDA limits above and Meta's prescription drug ad rules, covered in the platform section. "Same as Ozempic" fails the first test.
Can clinicians discuss off-label or investigational drugs publicly?
Yes, if you state the status plainly. FDA says that once a drug is approved, "healthcare providers generally may prescribe the drug for an unapproved use when they judge that it is medically appropriate," but that FDA hasn't determined those uses are safe and effective, in its off-label explainer.
Investigational drugs need the same clarity. Retatrutide, for example, is unapproved and can't be compounded under section 503A, Arent Fox Schiff notes. Discussing a trial is education. Presenting the drug as available is not.
Does "for research use only" protect peptide content?
No. On August 24, 2026, FDA sent warning letters to five peptide sellers. Each said that "despite statements on your product labeling," the website showed the products were "intended to be drugs for human use," according to Arent Fox Schiff's summary.
FDA cited specific evidence:
- NuScience Peptides sold bacteriostatic water with a "peptide calculator," which FDA called "a resource that provides the means to prepare an injectable drug for human administration."
- Royal Peptides offered bacteriostatic water alongside a "peptide guide" and "peptide calculator."
- Peptide Partners marketed bacteriostatic water for reconstitution, "providing the means to prepare an injectable drug for human administration," and used disease-related product claims.
A clinician who links to these sellers, or posts reconstitution math for their products, adds to the same evidence. Don't.
What does the FTC require for safety claims, testimonials, and case studies?
Evidence for every claim, including the ones you imply. The FTC's guidance says "a marketer is equally responsible for the accuracy of claims suggested or reasonably implied," and that health claims need "competent and reliable scientific evidence," generally randomized controlled human trials.
Testimonials don't fill that gap. The FTC says anecdotes "are never sufficient to substantiate claims about the effects of a health product," and that "a healthcare practitioner's observation about the effect of a health product on patients is anecdotal." The guidance covers all health products, so supplements, hormones, and peptides are held to the same evidence standard.
Paid relationships must be disclosed. On social media, the FTC says "the disclosure should be unavoidable," so a hyperlinked disclosure generally isn't enough.
Can a clinician say a peptide is safe or effective?
Only if competent and reliable scientific evidence supports that claim for that use. For most longevity peptides, it doesn't. FDA's safety risks page says the agency "lacks sufficient information to know whether" BPC-157 "would cause harm when administered to humans." Describe what has been studied, in whom, and what is unknown.
Are before-and-after posts allowed?
They are high risk. The FTC says "attempts to disclaim dramatic results with statements like 'Results not typical' don't cure the deception." Before-and-after images can also identify patients, which brings in HIPAA. In one HHS case, Complete P.T. paid $25,000 after posting patient testimonials with full names and full-face photos without valid HIPAA authorization.
How should you structure a clinician case study?
Make the reasoning the subject, not the result. This structure is Scriptura's suggestion:
- Patient presentation.
- Relevant history and labs.
- The clinical question.
- Risks and contraindications.
- Evidence considered.
- Monitoring plan.
- Clinician decision.
- Limitations.
Avoid the reverse pattern, which starts with a product, shows a dramatic result, and implies the product caused it.
If you include an outcome, state the time period, the objective data source, other care the patient received, the limitations, and whether the therapy was approved, off-label, compounded, or investigational. Get written authorization or fully de-identify, and have outcome posts reviewed before publishing. The FSMB guidelines say "patient privacy and confidentiality must be protected at all times."
So can doctors post patient peptide case studies? Yes, if the case is de-identified or authorized, centers the decision process, and makes no efficacy claim the evidence can't support.
What do the platforms allow?
Each platform sets its own healthcare social media rules, separates organic posts from paid ads, and paid rules are stricter. Check each policy again on the day you publish, because they change.
Instagram and Facebook
Can doctors talk about peptides on Instagram? Yes, as education. Meta's Oversight Board decision shows the platform recognizes medical context, but Meta initially removed that post, applied a strike, and kept an 18+ restriction even after restoring it. If a legitimate post is removed, appeal, and keep a copy of the post and its sources.
Paid ads are different. Meta requires a prescription drug ads authorization, and advertisers select a classification such as "Online Pharmacy" or "Telemedicine," according to LegitScript. Since August 25, 2021, telehealth providers and online pharmacies have needed LegitScript certification to promote prescription drugs in Meta ads, Foley & Lardner reported.
TikTok
Are peptide posts allowed on TikTok? Organic educational posts fall under TikTok's community rules. Paid content falls under separate ad rules, and those are tightly restricted. TikTok's healthcare and pharmaceuticals ad policy sets rules market by market. Many markets list prescription medicine as "Not allowed," and where it is permitted, TikTok requires proof of approval and an 18+ audience. Scriptura's suggestion: keep named-peptide TikTok content educational and review any paid campaign separately against the US section.
Can doctors discuss off-label drugs on LinkedIn? Yes, as clinician-to-clinician education, with the status stated. LinkedIn's ads policy, last revised November 18, 2025, says prescription drug ads are "restricted and require prior authorization," may run only in the United States and Canada, and can't target members under 18. Pharmacy and telehealth ads also need prior authorization and may run only in the United States.
Can a clinic link to a compounding pharmacy from social media? Scriptura's suggestion is to avoid purchase links, pharmacy checkout pages, and private contact offers for prescription drugs in organic posts on any platform. They turn education into access.
X
X's healthcare ad policy says "unless listed below, the promotion of health and pharmaceutical products and services is prohibited." Online pharmacies must be accredited by the National Association of Boards of Pharmacy. Telemedicine ads are permitted, but advertisers "may only target states within the United States in which they are licensed." The policy also covers products that claim to significantly influence "weight loss, or muscle growth." Research commentary in organic posts is a separate matter from these ad rules.
Which visuals and CTAs change the meaning of a post?
A post is read as a whole, so review the image, reel cover, thumbnail, caption, call to action, first comment, landing page, and any paid version together. The FTC's guidance holds advertisers responsible for each reasonable reading of an ad, so a careful caption doesn't rescue a misleading thumbnail.
Safer calls to action:
- Read the FDA update.
- Review the clinical trial.
- Save this for your next journal review.
- Talk with your licensed clinician about whether this applies to you.
High-risk calls to action:
- "Comment PEPTIDE, and we'll help you get it."
- "DM us to order."
- "Click here for compounded semaglutide."
- Coupon codes or prices for prescription or investigational products.
What should a healthcare social media compliance checklist include?
Run every post through these healthcare social media compliance questions before it goes live. This checklist is Scriptura's suggestion, not a legal standard:
- Does it state each product's status: approved, off-label, compounded, or investigational?
- Does every safety or efficacy claim, stated or implied, have a linked primary source?
- Is there any dosing, titration, stacking, reconstitution, injection, or calculator content? If so, remove it.
- Does any wording suggest a compounded drug is FDA-approved, generic, or the same as an approved drug?
- Is any patient identifiable? If so, is there written HIPAA authorization?
- Do the visuals, thumbnail, and first comment match the caption?
- Is the call to action educational, not access-oriented?
- Are paid relationships disclosed where viewers can't miss them?
- If it might be boosted, does it meet that platform's paid-ad rules?
- Has anyone reviewed state-specific legality or outcome claims?
What disclaimers are required for healthcare social media posts? Material connections must be disclosed. Beyond that, a disclaimer helps but cures nothing. The FTC says it "can't directly contradict a claim."
What is already on record, and what should you watch?
On record as of November 2, 2026:
- March 3, 2026: FDA warning letters to 30 telehealth companies over compounded GLP-1 marketing. About 25 more followed in mid-June.
- June 15, 2026: FDA's guidance page listing claims telehealth companies should avoid for compounded drugs.
- August 24, 2026: FDA warning letters to five peptide sellers rejecting "research use only" defenses.
- October 28, 2026: HHS's peptide enforcement discretion notice, which states that compounded drugs are not FDA-approved.
- October 29, 2026: Meta Oversight Board decision recognizing medical context in drug content.
Watch:
- New FDA warning letters to telehealth companies, clinics, and peptide sellers.
- The final version of the HHS peptide policy after its comment period.
- Meta's response to the Oversight Board's recommendations on medical exceptions.
- Changes to TikTok, LinkedIn, X, and Meta healthcare ad policies.
- State board guidance on clinician advertising and social media.
Frequently asked questions
Can physicians post about peptides on social media?
Yes, as education: status, evidence, risks, and clinical reasoning. Avoid dosing, sourcing, and efficacy claims the evidence doesn't support.
Can nurse practitioners or physician assistants advertise peptide therapy?
They can advertise services where state law allows. The FDA, FTC, and platform rules on claims apply to them exactly as they apply to physicians.
Does "for research use only" protect peptide marketing?
No. FDA's August 2026 letters looked past those labels to calculators, guides, and bacteriostatic water.
Can I say a compounded drug is the same as the brand?
No. FDA lists "the same as a drug approved by FDA" among claims to avoid.
Can doctors post patient case studies?
Yes, with authorization or full de-identification, a focus on clinical reasoning, and no unsupported outcome claims.
Are before-and-after weight-loss posts allowed?
They carry high FTC and HIPAA risk. "Results not typical" doesn't cure a misleading impression.
Can clinicians discuss investigational drugs?
Yes, as trial and evidence discussion. Don't present them as available treatments.
Do supplements follow different rules?
The FTC's evidence standard covers all health products. A supplement disclaimer "won't cure an otherwise deceptive ad."
What happens if a platform removes a legitimate medical post?
Appeal it, and keep the post and its sources. The Oversight Board's October 2026 decision shows removals can be reversed.
Do I need a disclaimer on every post?
A short educational disclaimer is good practice, but it doesn't fix a misleading claim. Required disclosures cover paid relationships.
About the author
How can Scriptura help clinicians who publish about peptides and hormones?
If you want every regulatory status you cite to be current and sourced before you post or prescribe, book a demo to see how Scriptura's clinical decision support keeps FDA and state board sources beside your clinical reasoning. Clinicians verify their license before platform access.
Educational and regulatory information only
This article is educational content only. It is not medical or legal advice and does not create an attorney-client or clinician-patient relationship. Privacy rules depend on your clinic's status and state. Confirm your obligations with a healthcare attorney licensed in your state before acting.
